Radiopharm Theranostics Ltd
NASDAQ:RADX
Radiopharm Theranostics Ltd
Operating Income
Radiopharm Theranostics Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Radiopharm Theranostics Ltd
ASX:RAD
|
Operating Income
-AU$37.1m
|
CAGR 3-Years
-325%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Operating Income
-$80.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Operating Income
$3.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Operating Income
AU$55.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Operating Income
AU$79.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Operating Income
-AU$48.5m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-25%
|
|
Radiopharm Theranostics Ltd
Glance View
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is a developer of platform of radiopharmaceutical products for both diagnostic and therapeutic uses. The company has a pipeline of four licensed platform technologies, namely Nano- monoclonal antibodies (mAbs) technology, Pivalate, AVb6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its clinical program includes five Phase I clinical trials, five Phase II clinical trials, and two Phase I clinical trials targeting a various cancer, including breast, lung, kidney, head and neck, pancreatic and brain. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, and RAD201 among others.
See Also
What is Radiopharm Theranostics Ltd's Operating Income?
Operating Income
-37.1m
AUD
Based on the financial report for Jun 30, 2024, Radiopharm Theranostics Ltd's Operating Income amounts to -37.1m AUD.
What is Radiopharm Theranostics Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
-325%
Over the last year, the Operating Income growth was -8%. The average annual Operating Income growth rates for Radiopharm Theranostics Ltd have been -325% over the past three years .
You don't have any saved screeners yet